Comparative Pharmacology
Head-to-head clinical analysis: MICROGESTIN FE 1 20 versus TRI LO LINYAH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICROGESTIN FE 1 20 versus TRI LO LINYAH.
MICROGESTIN FE 1/20 vs TRI-LO-LINYAH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol (estrogen) and norethindrone acetate (progestin). Suppresses gonadotropins via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation; increases cervical mucus viscosity and alters endometrial lining.
Combination estrogen-progestin oral contraceptive: suppresses gonadotropins (FSH and LH) via negative feedback, inhibiting ovulation; increases cervical mucus viscosity, reducing sperm penetration; alters endometrial structure, impairing implantation.
One tablet orally once daily, containing norethindrone acetate 1 mg and ethinyl estradiol 20 mcg, taken at the same time each day for 21 days followed by 7 days of placebo (iron tablets) or continuous cycling per prescribing information.
One tablet orally once daily for 21 days, followed by 7 days of placebo. Each tablet contains 0.180 mg norgestimate and 0.025 mg ethinyl estradiol for days 1-7, 0.215 mg/0.025 mg for days 8-14, and 0.250 mg/0.025 mg for days 15-21.
None Documented
None Documented
Norethindrone: 5-14 hours (mean 8 hours); Ethinyl estradiol: 12-24 hours (mean 18 hours); Steady-state in 5-7 days
Terminal elimination half-life: 12-15 hours; allows once-daily dosing but requires dose adjustment in renal impairment.
Renal: ~50-60% as metabolites; Fecal: ~30-40% as metabolites; Biliary: minor; <1% unchanged
Renal: ~60% as unchanged drug; fecal/biliary: ~40% as metabolites.
Category C
Category C
Oral Contraceptive
Oral Contraceptive